{
  "meta": {
    "title": "Thyroid_Part_2",
    "url": "https://brainandscalpel.vercel.app/thyroid-part-2-dada3cba.html",
    "scrapedAt": "2025-11-30T11:13:22.878Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Iron</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Folic acid</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Omeprazole</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following medications does not interfere with thyroxine absorption from the GIT?</span></p>",
      "unique_key": "DT1188632",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188632,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Levothyroxine absorption</strong> occurs primarily in the <strong>jejunum and ileum</strong>.</li>\n<li>Several medications interfere with its gastrointestinal absorption, including:\n<ul>\n<li><strong>Iron (Option A)</strong></li>\n<li><strong>Calcium salts (Option C)</strong></li>\n<li><strong>Proton pump inhibitors (PPIs)</strong> like <strong>omeprazole (Option D)</strong></li>\n<li><strong>H2 receptor blockers</strong></li>\n<li><strong>Cholestyramine, sucralfate, phosphate binders</strong></li>\n</ul>\n</li>\n<li>These drugs should be taken <strong>at least 4-6 hours apart</strong> from levothyroxine.</li>\n<li><strong>Folic acid</strong> does <strong>not interfere</strong> with thyroxine absorption and can be safely co-administered.<br /> </li>\n</ul>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">One hour before breakfast</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Along with the first bite of food in the morning</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Two hours after breakfast</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">At bedtime</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The ideal time for taking the thyroxine tablet is:</span></p>",
      "unique_key": "DT1188634",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188634,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Levothyroxine absorption</strong> occurs primarily in the <strong>proximal small intestine</strong>.</li>\n<li><strong>Bioavailability:</strong> ~70-80% when taken in the fasting state.</li>\n<li><strong>Food</strong>, dietary fibre, coffee, and many drugs <strong>interfere with its intestinal absorption. (Options B and C ruled out)</strong></li>\n<li>Therefore, the <strong>ideal time</strong> is <strong>in the morning, on an empty stomach, 1 hour before breakfast</strong>.</li>\n<li>Alternatively, it can be taken at <strong>bedtime</strong> (at least 3-4 hours after the evening meal), but consistency in timing is key. <strong>(Option D ruled out)</strong></li>\n</ul>\n<p><strong>Reference:</strong> Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):781-92.</p>",
      "correct_choice_id": 11,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Dyshormonogenesis</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Transcription factor defects causing secondary hypothyroidism</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroid dysgenesis</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroid hormone transporter defects</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The most common cause for congenital hypothyroidism is:</span></p>",
      "unique_key": "DT1188637",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188637,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Congenital hypothyroidism</strong> is one of the most common preventable causes of intellectual disability worldwide.</li>\n<li><strong>Thyroid dysgenesis</strong> (aplasia, hypoplasia, or ectopic thyroid) accounts for <strong>~85%</strong> of cases.</li>\n<li><strong>Dyshormonogenesis</strong> (enzyme defects in thyroid hormone synthesis) accounts for ~10-15% of cases and usually presents with <strong>goitre</strong>. <strong>(Option A ruled out)</strong></li>\n<li><strong>Clinical correlation:</strong>\n<ul>\n<li>Dysgenesis: no goitre</li>\n<li>Dyshormonogenesis: goitre present</li>\n</ul>\n</li>\n<li>Incidence:\n<ul>\n<li>~1 in 4000 in Western newborns</li>\n<li>~1 in 1000 in Indian newborns</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Transcription factor defects (Option B): </strong>Rare genetic causes leading to <strong>secondary (central) hypothyroidism</strong> due to pituitary or hypothalamic dysfunction.</p>\n<p><strong>Thyroid hormone transporter defects (Option D): </strong>Extremely rare. Cause impaired cellular entry of thyroid hormones, not a common cause of congenital hypothyroidism.</p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">It causes congenital hypothyroidism.</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Pendrin is the sodium-iodide symporter present in thyroid follicular cells</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">It is associated with sensorineural hearing loss</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">It is inherited in an autosomal recessive manner</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements about Pendred syndrome is incorrect?</span></p>",
      "unique_key": "DT1188639",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188639,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Pendred syndrome</strong> is an <strong>autosomal recessive disorder</strong> caused by mutations in the <strong>SLC26A4 gene</strong> on chromosome 7. <strong>(Option D)</strong></li>\n<li>It encodes <strong>Pendrin</strong>, a <strong>chloride-iodide transporter</strong> located on the <strong>apical membrane of thyroid follicular cells</strong>.</li>\n<li>Pendrin mediates iodide transport into the colloid, necessary for thyroid hormone synthesis.</li>\n<li>Pendred syndrome commonly presents with <strong>goitrous congenital hypothyroidism</strong> due to <strong>defective iodide organification. (Option A)</strong></li>\n<li><strong>Clinical features:</strong>\n<ul>\n<li><strong>Congenital hypothyroidism</strong> (goitrous, due to dyshormonogenesis)</li>\n<li><strong>Sensorineural hearing loss</strong> (with enlarged vestibular aqueduct) <strong>(Option C)</strong></li>\n</ul>\n</li>\n<li>The <strong>sodium-iodide symporter (NIS)</strong> is a different protein, located on the <strong>basolateral membrane</strong>, and mediates iodide uptake from blood into thyroid cells.</li>\n</ul>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Systemic steroids are of no value in managing the eye disease</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Orbital irradiation is commonly used to treat thyroid eye disease</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Corrective eye muscle surgery should now be considered</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Her thyroid eye disease may be worsened by radioiodine treatment</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman with relapsed Graves' disease. TSH is less than 0.05 mU/l, with a Free T4 of 32.5 pmol/l(9-20). She has severe bilateral thyroid eye disease with marked orbital oedema and proptosis. You are considering radiotherapy as she has failed drug treatment. Which of the following statements best fits the management of her thyroid eye disease?</span></p>",
      "unique_key": "DT1188641",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188641,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Radioiodine therapy</strong> can <strong>worsen or precipitate Graves' orbitopathy</strong>, especially in smokers and those with active, severe eye disease.</li>\n<li>In such patients, radioiodine should be avoided, or if essential, should be combined with <strong>glucocorticoid prophylaxis</strong>.</li>\n<li><strong>IV glucocorticoids</strong> are the first-line therapy for severe, active ophthalmopathy. <strong>(Option A ruled out)</strong></li>\n<li><strong>Orbital irradiation</strong> and other second-line therapies are considered only when steroids fail. <strong>(Option B ruled out)</strong></li>\n<li><strong>Corrective orbital or strabismus surgery</strong> is performed only after the eye disease has become <strong>inactive and stable for &ge;6 months</strong>. <strong>(Option C ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">De Quervain's thyroiditis</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Atrophic hypothyroidism</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Hashimoto's thyroiditis</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Grave's disease</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 34-year-old man comes to the clinic complaining of tiredness, lethargy and an increasingly hoarse voice. He also tells you that he has been losing his hair over the past few months and has noticed fullness in his neck; he has gained 7kg in the past 3 months. On examination, he has a puffy face and periorbital oedema, and there is a firm, rubbery goitre. His pulse is 48/min and regular, his BP 142/73 mmHg.<br>Investigations;<br>TSH 70.1 U/l<br>Total cholesterol 320 mg/dl<br>Triglycerides 290 mg/dl<br>LDL 150 mg/dl<br>FNA thyroid: Diffuse lymphocytic and plasma cell infiltration<br>Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1188645",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188645,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has <strong>classical hypothyroidism</strong> (bradycardia, weight gain, cold features, dyslipidemia).</li>\n<li>The firm, rubbery goitre with <strong>lymphocytic and plasma cell infiltration on FNA</strong> is diagnostic of <strong>Hashimoto's thyroiditis</strong>.</li>\n<li>It is the <strong>most common cause of hypothyroidism in iodine-sufficient areas</strong> and an <strong>autoimmune disease</strong> characterised by <strong>anti-TPO and anti-thyroglobulin antibodies</strong>.</li>\n<li>Strongly associated with other autoimmune diseases and family clustering.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>De Quervain's thyroiditis (Option A):</strong> A painful, post-viral thyroiditis with high ESR and transient thyrotoxicosis; not associated with antibodies or firm rubbery goitre.</p>\n<p><strong>Atrophic hypothyroidism (Option B):</strong> Autoimmune hypothyroidism with thyroid autoantibodies but <strong>no goitre</strong> (thyroid atrophy), unlike this case.</p>\n<p><strong>Graves' disease (Option D): </strong>Autoimmune hyperthyroidism with TSH receptor-stimulating antibodies, diffuse goitre, ophthalmopathy, and <strong>suppressed TSH</strong>, not hypothyroidism.</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">The elderly population are most often affected</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Has a mortality rate of around 30%</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypothermia, hyponatremia, and hypoglycemia are features</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Volume replenishment with hypotonic IV fluids followed by IV steroids is the initial treatment</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is incorrect regarding Myxedema coma?</span></p>",
      "unique_key": "DT1188648",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188648,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Volume resuscitation in myxedema coma should be initiated with <strong>isotonic (normal saline)</strong> or <strong>hypertonic saline</strong> if hyponatremia is severe; <strong>hypotonic fluids are contraindicated</strong>.</p>\n<p><strong>Myxedema coma</strong> is the <strong>most severe form of hypothyroidism</strong>, usually occurring in <strong>elderly women</strong> with untreated or undertreated hypothyroidism. <strong>(Option A)</strong></p>\n<p>It is commonly precipitated by <strong>infection, drugs (sedatives, hypnotics), MI, GI bleeding, or cold exposure</strong>.</p>\n<p>Clinical features: <strong>hypothermia, hypoventilation, hyponatremia, hypoglycemia, bradycardia, hypotension, and altered mental status</strong>. <strong>(Option C)</strong></p>\n<p><strong>Mortality is high (20-30%)</strong>, even with appropriate therapy. <strong>(Option B)</strong></p>\n<p><strong>Initial management:</strong></p>\n<ul>\n<li>IV <strong>hydrocortisone</strong> (to exclude concomitant adrenal insufficiency)</li>\n<li><strong>Large-dose IV/PO levothyroxine</strong> (sometimes liothyronine if severe)</li>\n<li><strong>Isotonic saline</strong> for resuscitation (hypertonic saline if severe hyponatremia).</li>\n</ul>\n<p><strong>Reference:</strong></p>\n<p><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK545193/\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/books/NBK545193/</a></p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Turner's syndrome</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Polycystic ovary disease</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypothyroidism</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Sheehan's syndrome</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The presence of galactorrhoea is most suggestive of which one of the following conditions?</span></p>",
      "unique_key": "DT1188653",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188653,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Galactorrhoea</strong> is the <strong>non-puerperal secretion of milk</strong> due to <strong>hyperprolactinaemia</strong>.</li>\n<li>In <strong>primary hypothyroidism</strong>, <strong>low T4/T3, elevated TRH</strong>, which stimulates both <strong>TSH and prolactin release</strong> from the pituitary.</li>\n<li>This leads to <strong>galactorrhoea, amenorrhoea, and decreased libido</strong> in some cases.</li>\n<li>Thus, hypothyroidism is a recognised cause of hyperprolactinaemia and galactorrhoea.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Turner's syndrome (Option A): </strong>Presents with <strong>primary ovarian failure, amenorrhoea, and underdeveloped breasts</strong>, but galactorrhoea is not a feature.</p>\n<p><strong>Polycystic ovary disease (Option B):</strong> May rarely be associated with mild prolactin elevation, but galactorrhoea is not a defining feature; main features are <strong>oligo/anovulation, hyperandrogenism, and polycystic ovaries</strong>.</p>\n<p><strong>Sheehan's syndrome (Option D):</strong> Postpartum pituitary necrosis causes <strong>failure of lactation</strong>, not galactorrhoea.</p>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Screening of family members for hypercholesterolaemia</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Lifestyle advice and reassurance</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Start high-dose statin therapy</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Check her TSH</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old, non-smoking woman with no previous cardiac history presents for cardiac risk-factor evaluation. Her total cholesterol is 350 mg/dl. She is overweight and has sleep apnoea. On examination, you notice her skin is particularly dry, and there appears to be some evidence of hair loss. What is the next step in her management?</span></p>",
      "unique_key": "DT1188654",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188654,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The combination of <strong>very high cholesterol</strong> with <strong>clinical features of hypothyroidism</strong> (dry skin, hair loss, obesity, sleep apnoea) suggests <strong>secondary hyperlipidemia due to hypothyroidism</strong>.</li>\n<li><strong>Hypothyroidism</strong> is a common and reversible cause of secondary dyslipidemia:\n<ul>\n<li>Occurs in ~4% of dyslipidemic patients as overt hypothyroidism.</li>\n<li>An additional ~10% have <strong>subclinical hypothyroidism</strong> (&uarr; TSH, normal free T4).</li>\n</ul>\n</li>\n<li>Checking <strong>TSH</strong> is crucial before initiating statins, as treating hypothyroidism with levothyroxine often <strong>normalises lipid levels</strong>.</li>\n<li>If dyslipidemia persists after euthyroidism is achieved, <strong>statin therapy</strong> may then be considered.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Screening of family members (Option A): </strong>Indicated in <strong>familial hypercholesterolemia</strong>, but not appropriate before excluding secondary causes such as hypothyroidism.</p>\n<p><strong>Lifestyle advice and reassurance (Option B):</strong> Helpful but insufficient, since a pathological secondary cause must be ruled out.</p>\n<p><strong>Start high-dose statin (Option C):</strong> Premature, as hypothyroidism should be excluded first; statins are added only if hyperlipidemia persists after thyroid correction.</p>",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Sick euthyroid syndrome</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Toxic nodule</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Grave's disease</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Subacute thyroiditis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 66-year-old man presents with lethargy and weight loss. This has gradually occurred over the last 6 months. On examination, a small goitre is palpable. There is no evidence of eye signs or pretibial myxedema.<br>Investigations reveal:<br>Free T4 - 21.1 (9.8-23) pmol/l<br>T3 - 5.3 (3.3-5.5) pmol/l<br>TSH - 0.05 (0.1-5) mU/l<br>Thyroid autoantibody titres are all negative.<br>A thyroid uptake scan showed focal uptake of radioisotope with suppressed uptake in the rest of the thyroid. What is the diagnosis?</span></p>",
      "unique_key": "DT1188656",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188656,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>This patient has <strong>subclinical hyperthyroidism</strong> (suppressed TSH, normal T3 and T4).</li>\n<li>The thyroid uptake scan shows <strong>focal uptake in a single nodule with suppression of surrounding thyroid tissue</strong>, which is diagnostic of a <strong>toxic (autonomous) nodule</strong>.</li>\n<li><strong>Pathogenesis:</strong> often due to activating mutations in the TSH recepto,r causing constitutive thyroid hormone production.</li>\n<li>More common in the <strong>elderly</strong>, and may present with subclinical or overt hyperthyroidism.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Sick euthyroid syndrome (Option A): </strong>Occurs in critically ill patients with altered thyroid function tests, not in stable outpatients.</p>\n<p><strong>Graves' disease (Option C):</strong> Typically shows <strong>diffuse homogeneous uptake</strong> on scintigraphy and positive thyroid autoantibodies, absent here.</p>\n<p><strong>Subacute thyroiditis (Option D): </strong>Presents with <strong>painful goitre</strong> and <strong>low/absent uptake</strong> on scan, not focal increased uptake.</p>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Most common cause for hyperthyroidism</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Smoking increases risk</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Common in males</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Referred as Toxic diffuse goitre</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements about Graves' disease is false?</span></p>",
      "unique_key": "DT1188658",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188658,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Graves' disease</strong> is the <strong>most common cause of hyperthyroidism worldwide</strong>, especially in women under 40 (<strong>women are affected about 10 times more frequently than men</strong>). <strong>(Option A)</strong></li>\n<li>It is an <strong>autoimmune condition</strong> caused by <strong>thyrotropin receptor antibodies (TRAb)</strong>, which stimulate the TSH receptor in the thyroid, orbit, and skin.</li>\n<li>Clinical features include <strong>diffuse goitre</strong>, hyperthyroid symptoms, <strong>Graves' ophthalmopathy</strong>, <strong>dermopathy</strong>, and rarely <strong>thyroid acropachy</strong>. <strong>(Option D)</strong></li>\n<li><strong>Smoking</strong> is a well-established risk factor for the development and severity of Graves' ophthalmopathy. <strong>(Option B)</strong></li>\n<li>Signs and symptoms:\n<ul>\n<li>Anxiety</li>\n<li>Irritability</li>\n<li>Heat sensitivity</li>\n<li>Increased perspiration/ warm and moist skin</li>\n<li>Weight loss</li>\n<li>Goitre (Glandular enlargement)</li>\n<li>Menstrual cycle changes</li>\n<li>Erectile dysfunction/ reduced libido</li>\n<li>Graves Ophthalmopathy - Bulging eyes - Exophthalmos</li>\n<li>Graves' dermopathy - thick, red skin on shins/top of feet.</li>\n<li>Thyroid acropachy - painless clubbing of fingers and toes</li>\n</ul>\n</li>\n</ul>",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Hashimoto's thyroiditis</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Grave's disease</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Iodine deficiency</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Post radioiodine treatment</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 37-year-old female presents with sweatiness, tremors and palpitations. Examination reveals an exophthalmos and a goitre. Her GP advised TFT's which show a TSH of 0.01mU/l, FT4 35 pmol/l(9-20), FT3 3.1 nmol/l. She has positive TSH receptor antibodies.<br>What is the likely diagnosis?</span></p>",
      "unique_key": "DT1188662",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188662,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Graves' disease</strong> is the <strong>most common cause of hyperthyroidism</strong> in young women.</li>\n<li>It is mediated by <strong>TSH receptor-stimulating antibodies (TRAb)</strong> that activate the TSH receptor, leading to thyroid hormone excess.</li>\n<li>Classical <strong>extrathyroidal features</strong>:\n<ul>\n<li><strong>Ophthalmopathy</strong> (exophthalmos, periorbital oedema, diplopia)</li>\n<li><strong>Dermopathy</strong> (pretibial myxedema)</li>\n<li><strong>Acropachy</strong> (digital clubbing)</li>\n</ul>\n</li>\n<li>Imaging:\n<ul>\n<li><strong>Ultrasound</strong>- diffuse gland enlargement with increased vascularity ('thyroid inferno').</li>\n<li><strong>Scintigraphy</strong>- diffuse, homogeneous uptake.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Hashimoto's thyroiditis (Option A):</strong> Autoimmune hypothyroidism with anti-TPO antibodies; can cause transient thyrotoxicosis (Hashitoxicosis) but does not present with exophthalmos or positive TRAb.</p>\n<p><strong>Iodine deficiency (Option C):</strong> Causes goitre and hypothyroidism, not hyperthyroidism with TRAb positivity.</p>\n<p><strong>Post-radioiodine treatment (Option D):</strong> Patients typically develop hypothyroidism after ablation, not active hyperthyroidism.</p>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroxine-binding globulin (TBG)</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Transthyretin (TTR)</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Albumin</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The maximum share of thyroid hormones circulates in the blood bound to which plasma protein?</span></p>",
      "unique_key": "DT1188665",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188665,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Thyroid hormones (<strong>T4 and T3</strong>) circulate in plasma primarily in a <strong>protein-bound form</strong>.</li>\n<li>The major binding proteins are:\n<ul>\n<li><strong>Thyroxine-binding globulin (TBG)</strong>: binds ~70% of circulating T4/T3 (highest affinity, lowest concentration).</li>\n<li><strong>Transthyretin (TTR, thyroxine-binding prealbumin)</strong>: binds ~10-15% of T4. <strong>(Option B ruled out)</strong></li>\n<li><strong>Albumin</strong>: binds ~15-20% of T4/T3 (low affinity, high capacity). <strong>(Option C ruled out)</strong></li>\n</ul>\n</li>\n<li>Only <strong>03% of T4</strong> and <strong>0.3% of T3</strong> are <strong>free (unbound)</strong>, and these free fractions are the <strong>biologically active forms</strong>.</li>\n</ul>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral contrast agents</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucocorticoids</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenytoin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">T4 to T3 conversion may be impaired by?</span></p>",
      "unique_key": "DT1188667",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188667,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Peripheral conversion of <strong>T4 (thyroxine) to T3 (active triiodothyronine)</strong> is mediated by <strong>5&prime;-deiodinase</strong>.</li>\n<li>Several factors inhibit this enzyme, including:\n<ul>\n<li><strong>Medications</strong>: <strong>propylthiouracil (PTU)</strong>, <strong>propranolol</strong>, <strong>amiodarone</strong>, and <strong>glucocorticoids</strong></li>\n<li><strong>Non-drug causes</strong>: fasting, systemic illness, acute trauma, and iodinated contrast agents</li>\n<li><strong>Amiodarone</strong> is a potent inhibitor of 5&prime;-deiodinase due to its <strong>high iodine content</strong> and direct enzyme inhibition, making it a classic cause of impaired T4 &rarr; T3 conversion.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Oral contrast agents (Option A):</strong> They can impair T4 &rarr; T3 conversion, but the <strong>best single answer</strong> here is amiodarone as the most recognised drug cause.</p>\n<p><strong>Glucocorticoids (Option C): </strong>High doses inhibit deiodinase and reduce T3, but amiodarone is a stronger and more specific answer.</p>\n<p><strong>Phenytoin (Option D):</strong> Does not inhibit conversion; instead, it <strong>displaces thyroid hormones from binding proteins</strong> (like salicylates, furosemide, free fatty acids).</p>",
      "correct_choice_id": 132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypothyroidism</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroid hormone resistance</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">First trimester of pregnancy</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">TSH-secreting pituitary tumor</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">TSH levels are elevated in all except?</span></p>",
      "unique_key": "DT1188668",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188668,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>TSH elevation</strong> occurs in:\n<ul>\n<li><strong>Primary hypothyroidism</strong>- the most common cause. <strong>(Option A)</strong></li>\n<li><strong>TSH-secreting pituitary adenoma</strong>- central hyperthyroidism with elevated TSH and thyroid hormones. <strong>(Option D)</strong></li>\n<li><strong>Thyroid hormone resistance</strong>- impaired tissue response, so feedback suppression of TSH does not occur. <strong>(Option B)</strong></li>\n</ul>\n</li>\n<li>In the <strong>first trimester of pregnancy</strong>, <strong>&beta;-hCG rises significantly</strong> and can weakly stimulate the <strong>TSH receptor</strong>, leading to <strong>physiological suppression of TSH</strong> (often &lt;0.1 mU/L).</li>\n<li>Therefore, the only condition among the options where <strong>TSH is not elevated</strong> is a <strong>first-trimester pregnancy</strong>.</li>\n</ul>",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">1</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">1.6</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">2</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">2.4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The average daily production of T4 in the body is around _______ mcg/kg</span></p>",
      "unique_key": "DT1188669",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188669,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The <strong>average daily production of thyroxine (T4)</strong> is approximately <strong>80-85 mcg/day</strong>, which equates to <strong>6-1.8 mcg/kg body weight</strong>.</li>\n<li>In patients with <strong>complete thyroid failure</strong>, the typical <strong>replacement dose of levothyroxine</strong> is also <strong>6-1.8 mcg/kg/day</strong>.</li>\n<li>Dose adjustments are guided by <strong>TSH measurement after 6-8 weeks</strong> of therapy, since steady-state levels are achieved only after several weeks due to thyroxine's long half-life (~7 days).</li>\n</ul>",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Stopped</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Unchanged</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a hypothyroid patient becoming pregnant, dose of levothyroxine should be?</span></p>",
      "unique_key": "DT1188675",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188675,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>During pregnancy, thyroid hormone requirements <strong>increase by 30-45%</strong>, so the levothyroxine dose must be adjusted upward.<strong> (Options B and D ruled out)</strong></li>\n<li>This increase is due to:\n<ol>\n<li><strong>hCG rise in the first trimester-</strong> weak TSH receptor stimulation.</li>\n<li><strong>Estrogen-induced TBG increase-</strong> higher bound fraction, requiring more hormone.</li>\n<li><strong>Altered immune system activity</strong> can influence autoimmune thyroid disease.</li>\n<li><strong>Placental type III deiodinase activity-</strong> accelerates thyroid hormone metabolism.</li>\n<li><strong>Increased urinary iodide excretion-</strong> may limit thyroid hormone synthesis in iodine-deficient areas.</li>\n</ol>\n</li>\n<li>After delivery, the levothyroxine dose is typically <strong>reduced back to pre-pregnancy levels</strong>.</li>\n<li>Hypothyroidism, untreated in pregnancy, risks <strong>miscarriage, preeclampsia, and impaired fetal neurodevelopment. (Option C ruled out)</strong></li>\n<li><strong>WHO recommends</strong>: Iodine intake of <strong>250 &mu;g/day</strong> in pregnancy &amp; lactation; prenatal vitamins should contain <strong>150 &mu;g/tablet</strong>.</li>\n</ul>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">1 %</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">5 %</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">10 %</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">25 %</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Endemic goiter is said to exist when more than ___ % of children aged 6-12 years have enlarged thyroid glands</span></p>",
      "unique_key": "DT1188676",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188676,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Endemic goitre</strong> is characterised by enlargement of the thyroid gland in a significantly large fraction of a population group, and is generally considered to be due to insufficient iodine in the daily diet.</li>\n<li>Endemic goitre exists in a population <strong>when &gt;5% of 6-12-year-old children</strong> have enlarged thyroid glands.</li>\n<li>Most mountainous districts in the world have been or still are endemic goitre regions.</li>\n</ul><p><strong>Reference:</strong> Eastman CJ, Zimmermann MB. The Iodine Deficiency Disorders. [Updated 2018 Feb 6]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext</p>",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Papillary thyroid cancer</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Follicular thyroid cancer</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Medullary thyroid cancer</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Anaplastic thyroid cancer</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">History of exposure to head and neck irradiation increases the risk of:</span></p>",
      "unique_key": "DT1188677",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188677,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Papillary thyroid carcinoma (PTC)</strong> is the <strong>most common thyroid cancer</strong> (~70-80%).</li>\n<li><strong>Radiation exposure</strong>, particularly to the <strong>head and neck during childhood or adolescence</strong>, is the strongest environmental risk factor for papillary carcinoma.</li>\n<li>Other risk factors: <strong>female sex, family history, and advanced age</strong>.</li>\n<li><strong>Histology:</strong> Characterised by <strong>Orphan Annie eye nuclei, nuclear grooves, and psammoma bodies</strong>.</li>\n<li>PTC typically spreads to <strong>cervical lymph nodes</strong>, but prognosis is generally excellent.<br /> </li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Follicular thyroid cancer (Option B): </strong>More common in <strong>iodine deficiency</strong> and multinodular goitre, spreads hematogenously (bone, lung).</p>\n<p><strong>Medullary thyroid cancer (Option C):</strong> Arises from <strong>C cells</strong>, associated with <strong>MEN-2 syndromes</strong> and RET mutations, not irradiation.</p>\n<p><strong>Anaplastic thyroid cancer (Option D):</strong> Aggressive tumour seen in the elderly, often arising from pre-existing differentiated thyroid cancers, but not linked to radiation exposure.</p>",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypothalamic pituitary causes</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Poor compliance with thyroxine supplements</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">The patient's results are as expected - no change in treatment is required</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Malabsorption syndrome</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient who has had a subtotal thyroidectomy for hyperthyroidism is on thyroxine replacement. She has a normal thyroid-stimulating hormone (TSH), normal tri-iodothyronine (T3) and low free thyroxine (T4) levels.<br>What is the most likely reason for those results?</span></p>",
      "unique_key": "DT1188679",
      "question_audio": null,
      "question_video": null,
      "map_id": 1188679,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>In patients on <strong>long-term thyroxine replacement</strong>, the <strong>most reliable indicator of adequacy</strong> of treatment is <strong>TSH</strong>.</li>\n<li>Even if <strong>free T4 appears low</strong>, as long as <strong>TSH is normal and the patient is clinically euthyroid</strong>, no change in therapy is required.</li>\n<li>Isolated low free T4 values may occur due to <strong>assay variability</strong> or altered binding proteins, but are not clinically significant when TSH is normal.</li>\n<li>Monitoring strategy: <strong>TSH every 1-3 years</strong> once stable on replacement therapy.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Hypothalamic-pituitary causes (Option A): </strong>Would cause <strong>low/normal TSH with low T4</strong>, but here TSH is normal, ruling out central hypothyroidism.</p>\n<p><strong>Poor compliance (Option B):</strong> Typically presents with <strong>fluctuating or elevated TSH</strong> and high dose requirements, not seen here.</p>\n<p><strong>Malabsorption syndrome (Option D):</strong> Would require <strong>excessive thyroxine doses (&gt;200 mcg/day)</strong> with abnormal TSH, not present in this patient.</p>",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}